HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CHSY3
chondroitin sulfate synthase 3
Chromosome 5 · 5q23.3
NCBI Gene: 337876Ensembl: ENSG00000198108.4HGNC: HGNC:24293UniProt: Q70JA7
21PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activityN-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activitychondroitin sulfate proteoglycan biosynthetic processGolgi membranevertebral joint diseasesmoking initiationCOVID-19severe acute respiratory syndrome
✦AI Summary

CHSY3 (chondroitin sulfate synthase 3) is a bifunctional glycosyltransferase that catalyzes chondroitin sulfate (CS) chain polymerization by sequentially transferring glucuronic acid and N-acetylgalactosamine residues to elongating CS polymers 1. The enzyme functions as part of heterodimeric complexes with CHPF or CHPF2, where CHSY3 provides catalytic activity while its binding partners stabilize the complex 1. Chain polymerization occurs through a non-processive, distributive mechanism 1. CHSY3 exhibits reduced specific activity compared to CHSY1. In disease contexts, CHSY3 demonstrates opposing roles: elevated expression in gastric cancer correlates with poor prognosis, promotes tumor cell proliferation and migration, and reduces immunotherapy benefit through increased tumor-associated macrophage infiltration 23. Conversely, CHSY3 depletion causes spontaneous intervertebral disc degeneration through disrupted actin-mediated YAP1 signaling in nucleus pulposus cells, highlighting CS's critical role in maintaining tissue homeostasis 4. In lung cancer, CHSY3 downregulation is associated with advanced disease stage and poor prognosis 5. In hepatocellular carcinoma, CHSY3 expression within decorin-expressing stromal cells correlates with better outcomes 6. These findings establish CHSY3 as a context-dependent regulator with potential as a therapeutic target.

Sources cited
1
CHSY3 is a bifunctional glycosyltransferase that forms heterodimeric complexes with CHPF or CHPF2; catalyzes CS chain polymerization through non-processive, distributive mechanism
PMID: 41298522
2
High CHSY3 expression in gastric cancer promotes proliferation and migration, is associated with poor prognosis, and reduces immunotherapy benefit through increased TAM infiltration
PMID: 37461041
3
CHSY3 upregulation in gastric cancer correlates with advanced tumor stage, higher recurrence risk, worse survival, and increased TAM infiltration; knockdown reduces cell proliferation and migration
PMID: 38812506
4
CHSY3 knockout causes spontaneous intervertebral disc degeneration through actin-mediated YAP1 signaling activation, independent of canonical Hippo/Lats pathway
PMID: 33089528
5
CHSY3 expression is decreased in non-small cell lung cancer patients; downregulation correlates with advanced TNM stage and poor prognosis
PMID: 34525476
6
In hepatocellular carcinoma, CHSY3 is part of a decorin-associated stromal signature; CS-DCN-expressing stromal cells with elevated CHSY3 correlate with better prognosis and reduced invasiveness
PMID: 40420150
Disease Associationsⓘ20
vertebral joint diseaseOpen Targets
0.29Weak
smoking initiationOpen Targets
0.29Weak
COVID-19Open Targets
0.29Weak
severe acute respiratory syndromeOpen Targets
0.29Weak
osteoarthritisOpen Targets
0.27Weak
psoriatic arthritisOpen Targets
0.26Weak
Crohn's diseaseOpen Targets
0.26Weak
cervical carcinomaOpen Targets
0.26Weak
inflammatory bowel diseaseOpen Targets
0.26Weak
ovarian neoplasmOpen Targets
0.25Weak
pernicious anemiaOpen Targets
0.24Weak
asthmaOpen Targets
0.24Weak
preeclampsiaOpen Targets
0.23Weak
sarcoidosisOpen Targets
0.21Weak
intracranial hemorrhageOpen Targets
0.18Weak
Non-Neoplastic Bile Duct DisorderOpen Targets
0.17Weak
placenta praeviaOpen Targets
0.16Weak
breast benign neoplasmOpen Targets
0.15Weak
self-injurious ideationOpen Targets
0.15Weak
non-suppurative otitis mediaOpen Targets
0.12Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
CHPF2Protein interaction90%CHPFProtein interaction90%CSGALNACT1Protein interaction85%GALNT3Protein interaction76%CHSY1Protein interaction65%CSGALNACT2Protein interaction65%
Tissue Expression6 tissues
Liver
100%
Brain
81%
Lung
58%
Heart
57%
Ovary
17%
Bone Marrow
8%
Gene Interaction Network
Click a node to explore
CHSY3CHPF2CHPFCSGALNACT1GALNT3CHSY1CSGALNACT2
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q70JA7
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.89LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.65 [0.48–0.89]
RankingsWhere CHSY3 stands among ~20K protein-coding genes
  • #13,867of 20,598
    Most Researched21
  • #8,004of 17,882
    Most Constrained (LOEUF)0.89
Genes detectedCHSY3
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
CHSY3 promotes proliferation and migration in gastric cancer and is associated with immune infiltration.
PMID: 37461041
J Transl Med · 2023
1.00
2
Chondroitin synthase-3 regulates nucleus pulposus degeneration through actin-induced YAP signaling.
PMID: 33089528
FASEB J · 2020
0.90
3
Structural basis for human chondroitin sulfate chain polymerization.
PMID: 41298522
Nat Commun · 2025
0.80
4
The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.
PMID: 38812506
Front Immunol · 2024
0.70
5
Expression and Clinical Significance of lncRNA OSER1-AS1 in Peripheral Blood of Patients with Non-Small Cell Lung Cancer.
PMID: 34525476
Cells Tissues Organs · 2022
0.60